new_0222_0546|FMTX|0|total_current_assets|cash_on_hand|inventories_net|net_ppe|goodwill_and_intangible|liabilities|total_current_liabilities|total_long_term_liab|total_deposits|book_value_of_equity|retained_earnings|treasury_stock|ev_revenues|ev_earnings|ev_free_cash_flow|ev_assets|ps_ratio|pe_ratio|price_to_book_value|peg_ratio|debt_equity_ratio|dividend_yield|shareholder_yield_ttm|percent_of_shares_outstanding|receivables|payables|capital_stock|return_on_invested_capital|quality_ratio_fractile|momentum_fractile|market_beta_12_month|sustainable_growth_rate|institutional_investor_ownership_percentage|average_shares_outs_diluted|total_employee_number|eps|sga_expense|shares_outstanding|repurchase_of_capital_stock|ordinary_shares_number|payout_ratio|quick_ratio|normalized_eps|stock_buyback|effective_tax_rate|return_on_equity|net_income_ttm|revenues_ttm|dividend_per_share|revenues|gross_profit|pre_tax_income|net_income|interest_income|price|total_return_price|enterprise_value|average_volume_30|one_year_return|short_interest|forward_pe_ratio|forward_pe_ratio_1y|forward_ps_ratio|forward_ps_ratio_1y|quarterly_eps_estimates|quarterly_sales_estimates|quarterly_eps_surprise|quarterly_sales_surprise|quarterly_eps_actual|quarterly_sales_actual|sales_est_0y|sales_est_1y|price_target|consensus_recommendation|price_target_num_est|eps_est_0y|eps_est_1y|r_and_d_expense|reconciled_depreciation|interest_expense_non_operating|land_and_improvements|buildings_and_improvements|other_properties|machinery_furniture_equipment|price_next_month|price_second_month
new_0222_0546|FMTX|1|Forma Therapeutics Holdings Inc Total Current Assets (Quarterly) (USD)|Forma Therapeutics Holdings Inc Cash and Short Term Investments (Quarterly) (USD)|Forma Therapeutics Holdings Inc Inventories (Quarterly) (USD)|Forma Therapeutics Holdings Inc Net PP&E (Quarterly) (USD)|Forma Therapeutics Holdings Inc Goodwill and Intangibles (Quarterly) (USD)|Forma Therapeutics Holdings Inc Total Liabilities (Quarterly) (USD)|Forma Therapeutics Holdings Inc Total Current Liabilities (Quarterly) (USD)|Forma Therapeutics Holdings Inc Total Long Term Liabilities (Quarterly) (USD)|Forma Therapeutics Holdings Inc Total Deposits (Quarterly) (USD)|Forma Therapeutics Holdings Inc Book Value (Quarterly) (USD)|Forma Therapeutics Holdings Inc Retained Earnings (Quarterly) (USD)|Forma Therapeutics Holdings Inc Treasury Stock (Quarterly) (USD)|Forma Therapeutics Holdings Inc EV to Revenues|Forma Therapeutics Holdings Inc EV to Earnings|Forma Therapeutics Holdings Inc EV to Free Cash Flow|Forma Therapeutics Holdings Inc EV to Assets (Quarterly)|Forma Therapeutics Holdings Inc PS Ratio|Forma Therapeutics Holdings Inc PE Ratio|Forma Therapeutics Holdings Inc Price to Book Value|Forma Therapeutics Holdings Inc PEG Ratio|Forma Therapeutics Holdings Inc Debt to Equity Ratio|Forma Therapeutics Holdings Inc Dividend Yield|Forma Therapeutics Holdings Inc Shareholder Yield (TTM)|Forma Therapeutics Holdings Inc Percent of Shares Outstanding Short|Forma Therapeutics Holdings Inc Total Receivables (Quarterly) (USD)|Forma Therapeutics Holdings Inc Total Payables (Quarterly) (USD)|Forma Therapeutics Holdings Inc Total Capital Stock (Quarterly) (USD)|Forma Therapeutics Holdings Inc Return on Invested Capital|Forma Therapeutics Holdings Inc Quality Ratio Score|Forma Therapeutics Holdings Inc Momentum Score|Forma Therapeutics Holdings Inc Beta (1Y)|Forma Therapeutics Holdings Inc Sustainable Growth Rate (TTM)|Forma Therapeutics Holdings Inc Institutional Investor Ownership Percentage|Forma Therapeutics Holdings Inc Average Diluted Shares Outstanding (Quarterly)|Forma Therapeutics Holdings Inc Total Employees (Annual)|Forma Therapeutics Holdings Inc EPS Diluted (Quarterly) (USD)|Forma Therapeutics Holdings Inc SG&A Expense (Quarterly) (USD)|Forma Therapeutics Holdings Inc Shares Outstanding|Forma Therapeutics Holdings Inc Repurchase of Capital Stock (Quarterly) (USD)|Forma Therapeutics Holdings Inc Ordinary Shares Number (Quarterly)|Forma Therapeutics Holdings Inc Payout Ratio|Forma Therapeutics Holdings Inc Quick Ratio (Quarterly)|Forma Therapeutics Holdings Inc Normalized Diluted EPS (Quarterly) (USD)|Forma Therapeutics Holdings Inc Stock Buybacks (Quarterly) (USD)|Forma Therapeutics Holdings Inc Effective Tax Rate (TTM)|Forma Therapeutics Holdings Inc Return on Equity|Forma Therapeutics Holdings Inc Net Income (TTM) (USD)|Forma Therapeutics Holdings Inc Revenue (TTM) (USD)|Forma Therapeutics Holdings Inc Dividend Per Share (Quarterly) (USD)|Forma Therapeutics Holdings Inc Revenue (Quarterly) (USD)|Forma Therapeutics Holdings Inc Gross Profit (Quarterly) (USD)|Forma Therapeutics Holdings Inc Pre-Tax Income (Quarterly) (USD)|Forma Therapeutics Holdings Inc Net Income (Quarterly) (USD)|Forma Therapeutics Holdings Inc Net Interest Income (Quarterly) (USD)|Forma Therapeutics Holdings Inc Price (USD)|Forma Therapeutics Holdings Inc Total Return Price (USD)|Forma Therapeutics Holdings Inc Enterprise Value (USD)|Forma Therapeutics Holdings Inc 30-Day Average Daily Volume|Forma Therapeutics Holdings Inc 1 Year Price Returns (Daily)|Forma Therapeutics Holdings Inc Short Interest|Forma Therapeutics Holdings Inc PE Ratio (Forward)|Forma Therapeutics Holdings Inc PE Ratio (Forward 1y)|Forma Therapeutics Holdings Inc PS Ratio (Forward)|Forma Therapeutics Holdings Inc PS Ratio (Forward 1y)|Forma Therapeutics Holdings Inc Quarterly EPS Estimates (USD)|Forma Therapeutics Holdings Inc Quarterly Revenue Estimates (USD)|Forma Therapeutics Holdings Inc Quarterly EPS Surprise|Forma Therapeutics Holdings Inc Quarterly Revenue Surprise|Forma Therapeutics Holdings Inc Quarterly Actual EPS (USD)|Forma Therapeutics Holdings Inc Quarterly Actual Revenue (USD)|Forma Therapeutics Holdings Inc Revenue Estimates for Current Fiscal Year (USD)|Forma Therapeutics Holdings Inc Revenue Estimates for Next Fiscal Year (USD)|Forma Therapeutics Holdings Inc Price Target (USD)|Forma Therapeutics Holdings Inc Consensus Recommendation|Forma Therapeutics Holdings Inc Price Target Num Estimates|Forma Therapeutics Holdings Inc EPS Estimates for Current Fiscal Year (USD)|Forma Therapeutics Holdings Inc EPS Estimates for Next Fiscal Year (USD)|Forma Therapeutics Holdings Inc Research and Development Expense (Quarterly) (USD)|Forma Therapeutics Holdings Inc Reconciled Depreciation (Quarterly) (USD)|Forma Therapeutics Holdings Inc Non-Operating Interest Expense (Quarterly) (USD)|Forma Therapeutics Holdings Inc Land and Improvements (Quarterly) (USD)|Forma Therapeutics Holdings Inc Buildings and Improvements (Quarterly) (USD)|Forma Therapeutics Holdings Inc Other Properties (Quarterly) (USD)|Forma Therapeutics Holdings Inc Machine, Furniture & Equipment (Quarterly) (USD)||
new_0222_0546|FMTX|2|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|percent_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_beta|percent_USD_metric|percent_USD_metric|mil_figure_USD_metric|figure_whole_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_money_USD_price|mil_figure_money_USD_metric|figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_per_share_metric|percent_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_USD_metric|figure_whole_USD_price|figure_money_USD_per_share_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric||
new_0222_0546|FMTX|4|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|daily|quarterly|daily|quarterly|daily|quarterly|quarterly|daily|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|daily|monthly|quarterly|quarterly|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|monthly|monthly|monthly|monthly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly||
new_0222_0546|FMTX|5|91.2857142857|91.2857142857||91.2857142857||91.2857142857|91.2857142857|91.2857142857||91.2857142857|91.2857142857||1.44655581948|91.4|1.44655581948|91.4|1.44655581948||1.44655581948|||1.44655581948||15.2631578947|91.2857142857|91.2857142857|91.2857142857|||30.6666666667|30.7142857143|||91.4|172.666666667|91.4|91.4|32||91.2857142857|||91.4|91.4444444444|91.2857142857||91.2857142857|||91.6666666667||91.4|91.4|91.4|1.44655581948|1.44655581948|1.44655581948|1.44642857143|1.43195266272|15.2631578947|||1.44117647059|1.44755244755|91.4|91.4|91.4|92|91.4|91.4|24.1666666667|32.2222222222|19.4333333333|10.2280701754|19.4333333333|16.5714285714|19.3333333333|91.4|91.4||||91.2857142857|91.2857142857||
new_0222_0546|FMTX|6|7|7||7||7|7|7||7|7||421|5|421|5|421||421|||421||38|7|7|7|||6|7|||10|3|10|10|16||7|||10|9|7||7|||3||10|10|10|421|421|421|392|169|38|||34|286|10|10|5|1|5|5|24|18|30|57|30|35|30|10|10||||7|7||
new_0222_0546|FMTX|7|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|daily|quarterly|daily|daily|daily|daily|quarterly|daily|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|monthly|quarterly|yearly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|market_daily|market_daily|daily|market_daily|market_daily|daily|daily|daily|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|daily|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly||
new_0222_0546|FMTX|201903||||||||||||||||||||||||||||||||||27.0362||0.1987|4.918||||||0.3545|||||||72.009||35.713|35.605|1.197||||||||||||||||||||||||28.65|0.855|||||||
new_0222_0546|FMTX|201906||||||||||||||||||||||||||||||||||27.0362||-0.6145|5.688||||||-0.5173|||||||17.727||-16.082|-14.757|0.782||||||||||||||||||||||||28.065|0.682|||||||
new_0222_0546|FMTX|201909||||||||||||||||||||||||||||||||||27.0362||-1.2666|7.025||||||-1.1332|||||||3.377||-30.985|-30.985|0.565||||||||||||||||||||||||27.558|0.591|||||||
new_0222_0546|FMTX|201912|177.313|173.18||5.102||59.837|24.868|34.969||17.861|16.74||||||||||||||0.819|3.521|105.339|||||||27.0362||-1.1528|6.771|||36.7795|-130.3624|6.9969|-0.9404||5.0435||-34.793|100.557||7.444||-25.287|-24.656|0.306||||||||||||||||||||||||27.042|0.54||||16.377|5.439||
new_0222_0546|FMTX|202003|176.626|142.436||2.239||24.383|21.878|2.505||168|26.034||||||||||||||30.905|1.961|0.024|||||||36.7795|80|0.1587|8.933|||36.7795|||-0.1036||26.5988||-59.168|||||-8.255|11.23|0.641||||||||||||||||||||||||23.21|0.543||||5.346|4.969||
new_0222_0546|FMTX|202006|455.116|414.301||1.901||29.015|24.818|4.197||438.497|-1.206||16.0012|-46.246|-16.9285|8.7909|11.1877||4.6143|||||0.3725|37.6|3.753|0.041|||||||5.9432||-4.58|6.448|43.522||43.522|||-4.1898|-295.125|25.0566||-69.851|||||-28.678|-25.44|0.895|46.49|46.49|1609.0368|188818.5||162102|||||-0.663||0.0754||-0.6625||1.6667|1.6667|57.3333|1.3333|3|-1.918|-3.2093|20.511|0.284||||5.009|4.994|34.96|43.93
new_0222_0546|FMTX|202009|415.661|366.753||1.672||31.794|30.666|1.128||415.602|-28.822||17.9637|-51.9178|-19.2055|9.869|13.7351||5.2289|||||3.7018|42.337|4.168|0.041||||||87.6167|41.0889||-0.67|7.46|43.6021||43.6021|||-0.6689|1.418|29.0041||-66.482|||||-31.422|-27.616|0.87|49.84|49.84|1806.3757|271051.1||1614067|||||-0.6767|0.375|0.9857|-100|-0.67||0.75|1.25|56.25|1.5|4|-2.5467|-2.925|24.78|0.249||||5.028|4.994|43.12|43.74
new_0222_0546|FMTX|202012|654.447|633.054||1.52||32.727|31.7|1.027||648.244|-57.41||10.9727|-31.7126|-11.5335|6.0282|11.5891||2.6787|||||5.1222|15.273|4.596|0.047|||||||49.7545|107|-0.68|7.941|49.7545||49.7545|||-0.7282|-258.764|29.6795||-70.414|||||-31.778|-28.588|1.022|34.9|34.9|1103.378|551642.5||2548510||||758.5024|-0.788|0.1667|13.7056|-100|-0.68||0.1667|11|61.6|1.4|5|-3.6325|-3.252|24.866|0.2||||4.56|5.103|38.63|38.61
new_0222_0546|FMTX|202103|573.868|550.728||8.347||33.771|28.557|5.214||616.465|-93.37||8.4095|-24.3047|-8.1711|4.6201|10.037||2.2651|||||11.4168|17.075|3.301|0.047|||||||47.295||-0.76|9.867|49.8344||49.8344|||-0.76||7.9997||-117.604|||||-35.952|-35.96|0.262|28.02|28.02|845.6319|619861||5689518||||609.9533|-0.76||||-0.76|||1.1603|60.6667|1.3333|6|-3.18|-3.818|26.343|0.183||||11.529|5.144|26.95|28.07
new_0222_0546|FMTX|202106|557.924|535.558||5.185||33.974|31.1|2.874||579.395|-136.955||7.0157|-20.2763|-6.2599|3.8543|11.4774||2.1419|||||6.4072|15.236|5.128|0.047|||1|-0.3663|||47.3395|139|-0.92|12.471|49.8607||49.8607|||-0.9242||4.8237||-135.749|||||-43.477|-43.585|0.309|24.89|24.89|705.4748|396918.2333|-46.4616|3194687||||542.1038|-0.7929||-16.0356||-0.92||8.3333|1.2542|56.5|1.3333|6|-3.105|-3.6267|31.587|0.177||||8.461|5.167|22.89|24.03
new_0222_0546|FMTX|202109|534.886|512.681||35.31||59.394|32.634|26.76||542.831|-180.249||6.4056|-18.5131|-5.1638|3.5191|11.0554||2.1311|||||4.9133|19.018|4.64|0.047|||2|-0.2067|||47.3657|156|-0.91|12.749|49.8839||49.8839|||-0.9089||1.9852||-151.427|||||-43.287|-43.294|0.216|23.19|23.19|644.1266|329936.5|-53.4711|2450945||||505.3128|-0.9614||5.3493||-0.91|||2.2893|56.2857|1.2857|7|-3.49|-4.1083|30.684|0.312||||24.168|3.089|18.56|14.49
new_0222_0546|FMTX|202112|||||||||||||1.9595||-1.5796||6.7791||1.3075|||||3.9783||||||1|-1.1281||||||||||||||||||||||||14.22|14.22|197.0449|418844.1|-59.255|1985570|||564.9379|112.9238|-0.965||||||0.6323|1.2563|52.2857|1.2857|7|-3.56|-3.86||||||||11.84|10.62
new_0222_0546|FMTX|202203|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.9725|||||||||||||||||||||
new_0222_0546|FMTX|202206|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.9925|||||||||||||||||||||
new_0222_0546|FMTX|202209|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-1.015|||||||||||||||||||||
new_0222_0546|FMTX|202212|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-1.0075|0.4485||||||||||||||||||||